Biolegend, 506509, APC anti-human IFN-γ Antibody, 25tests

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells. The B27 antibody reacts with the human interferon-γ. The B27 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.
25tests
Verified Reactivity: Human
Reported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus, African Green, Pigtailed Macaque, Sooty Mangabey
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: E. coli-expressed recombinant human IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: Flow Cytometry2: The fluorochrome-labeled B27 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-? -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.Neutralization1,3,6,7: The Ultra-LEAF™ Purified antibody (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IFN-? bioactivity (Cat. No. 506531).
Application References(PubMed link indicates BioLegend citation): Favre C, et al. 1989. Molec. Immunol. 26:17. (Neut) Kaur A, et al. 2002. J Virol. 76:3646. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. Rout N, et al. 2010. PLoS One 5:e9787. (FC) Acosta-Rodriguez EV, et al. 2007. Nat. Immunol. 9:942-9. (Neut) Gangur V, et al. 1998. FASEB J. 12:705-13. (Neut)
Product Citations: Yang Y, et al. 2023. MBio. 14:e0328522. PubMed Saeland E, et al. 2023. NPJ Vaccines. 8:45. PubMed Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed Han Z, et al. 2022. J Invest Dermatol. 142:603. PubMed Yen M, et al. 2022. Cell. 185:1414. PubMed Laurent A, et al. 2014. PLoS One. 9:103683. PubMed Nesterenko PA, et al. 2021. Cell Rep. 37:110167. PubMed Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed Marques RM, et al. 2021. Cell Death Differ. 28:3140. PubMed Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed Costa-Martins AG, et al. 2021. Cell Rep Med. 2:100465. PubMed Shi Z, et al. 2021. Ann Clin Transl Neurol. 8:43. PubMed Blandine Monel et al. 2019. Cell reports. 27(1):142-153 . PubMed Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed Juno JA, et al. 2020. Nat Med. 26:1428. PubMed Rölle A, et al. 2018. Cell Rep. 24:1967. PubMed Torres-Ruiz J, et al. 2021. Front Immunol. 12:689966. PubMed Alrubayyi A, et al. 2021. Nat Commun. 12:5839. PubMed Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed Godbersen C, et al. 2017. Mol Cancer Ther. 16:1335. PubMed Zhuang X, et al. 2019. Cancer Immunol Res. 0.94375. PubMed Johnson JK, et al. 2022. Methods Mol Biol. 2470:641. PubMed Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed Matsuzawa T, et al. 2017. J Dermatol Sci. 10.1016/j.jdermsci.2017.03.015. PubMed Salvany‐Celades M et al. 2019. Cell Rep. 27(9):2537-2547 . PubMed Qiu X, et al. 2013. Sci Transl Med. 16:207. PubMed Robert R, et al. 2017. PLoS One. 10.1371/journal.pone.0184278. PubMed Min HK, et al. 2021. Immune Netw. 21:e43. PubMed Marzan-Rivera N, et al. 2022. iScience. 25:104764. PubMed Lee IK, et al. 2020. Cancers (Basel). 12:. PubMed Nesterenko PA, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
RRID: AB_315443 (BioLegend Cat. No. 506510)
Structure: Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID: 3458
UniProt: View information about IFN-gamma on UniProt.org
Clone: B27
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Isotype: Mouse IgG1, κ